| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Jenny P-Y Ting | |
| Haitao Guo | |||
| Justin B Callaway | |||
| P2860 | cites work | Parkinson's Disease: Genetics and Pathogenesis | Q22242000 |
| Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1 | Q24291293 | ||
| Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome | Q24303046 | ||
| The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta | Q24305136 | ||
| AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC | Q24319706 | ||
| AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA | Q24319765 | ||
| Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes | Q24339219 | ||
| NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice | Q24604235 | ||
| Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients | Q24631987 | ||
| The NAIP/NLRC4 inflammasomes | Q26829603 | ||
| Regulation of inflammasome signaling | Q26996605 | ||
| An Update on PYRIN Domain-Containing Pattern Recognition Receptors: From Immunity to Pathology | Q27004333 | ||
| Mechanisms of inflammasome activation: recent advances and novel insights | Q27005760 | ||
| The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis | Q27325503 | ||
| Structure of the Absent in Melanoma 2 (AIM2) Pyrin Domain Provides Insights into the Mechanisms of AIM2 Autoinhibition and Inflammasome Assembly | Q27677057 | ||
| Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor | Q27678368 | ||
| Obesity is associated with macrophage accumulation in adipose tissue | Q27860976 | ||
| Pattern recognition receptors and inflammation | Q27861115 | ||
| Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance | Q28131660 | ||
| Protein misfolding, functional amyloid, and human disease | Q28131732 | ||
| The PYRIN-CARD protein ASC is an activating adaptor for caspase-1 | Q28215427 | ||
| The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation | Q28242537 | ||
| Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein | Q28264162 | ||
| Multiple sclerosis | Q28299151 | ||
| Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain | Q28387719 | ||
| Inflammasomes and metabolic disorders: old genes in modern diseases | Q28389531 | ||
| The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes | Q28478561 | ||
| Non-canonical inflammasome activation targets caspase-11 | Q28506831 | ||
| CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation | Q28506984 | ||
| Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis | Q28507389 | ||
| Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity | Q28508255 | ||
| IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome | Q28574307 | ||
| Phosphorylation of NLRC4 is critical for inflammasome activation | Q28586109 | ||
| Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice | Q28591350 | ||
| Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme | Q28610362 | ||
| Thioredoxin-interacting protein links oxidative stress to inflammasome activation | Q29614471 | ||
| Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon | Q42201187 | ||
| Inhibition of IL-1beta improves fatigue in type 2 diabetes. | Q42919291 | ||
| Noncanonical inflammasome activation by intracellular LPS independent of TLR4. | Q44450840 | ||
| Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis | Q46323475 | ||
| Autoproteolytic activation of pro-caspases by oligomerization | Q47862735 | ||
| Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. | Q48449950 | ||
| Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production | Q50335883 | ||
| Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. | Q50336167 | ||
| Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. | Q50870985 | ||
| Obesity development in caspase-1-deficient mice. | Q50978244 | ||
| Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. | Q51308775 | ||
| Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by Porphyromonas gingivalis in human cells. | Q51833225 | ||
| The Inflammasome Sensor, NLRP3, Regulates CNS Inflammation and Demyelination via Caspase-1 and Interleukin-18 | Q53287408 | ||
| Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation | Q57258441 | ||
| Interleukin-18/Interleukin-18 Binding Protein Signaling Modulates Atherosclerotic Lesion Development and Stability | Q58150092 | ||
| Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice | Q62735862 | ||
| The Inflammasome in Atherosclerosis and Type 2 Diabetes | Q62818661 | ||
| IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha | Q68011992 | ||
| IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells | Q74279845 | ||
| Caspase-1 regulates the inflammatory process leading to autoimmune demyelination | Q78145110 | ||
| Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice | Q83630548 | ||
| Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance | Q83864443 | ||
| Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide | Q37499640 | ||
| FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. | Q37601031 | ||
| Blockade of interleukin 1 in type 1 diabetes mellitus | Q37696271 | ||
| Atherosclerosis: current pathogenesis and therapeutic options | Q37953777 | ||
| Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease | Q37968039 | ||
| The inflammasome puts obesity in the danger zone | Q37973832 | ||
| Inflammasomes and their roles in health and disease | Q38043048 | ||
| Mechanisms of NOD-like receptor-associated inflammasome activation | Q38140207 | ||
| Mechanisms and functions of inflammasomes | Q38214128 | ||
| Functions of caspase 8: the identified and the mysterious | Q38214149 | ||
| Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes | Q38245095 | ||
| Innate immunity in Alzheimer's disease | Q38358574 | ||
| The NLRP1 inflammasomes | Q38423366 | ||
| Caspase-8 functions as a key mediator of inflammation and pro-IL-1β processing via both canonical and non-canonical pathways | Q38423395 | ||
| Molecular basis for specific recognition of bacterial ligands by NAIP/NLRC4 inflammasomes | Q38777413 | ||
| Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation | Q38957581 | ||
| Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin | Q38971364 | ||
| The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. | Q39473693 | ||
| Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice | Q40506477 | ||
| Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome | Q41574826 | ||
| Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis. | Q41744836 | ||
| Cutting edge: Mouse NAIP1 detects the type III secretion system needle protein | Q41883043 | ||
| Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock | Q41970918 | ||
| Salmonella infection induces recruitment of Caspase-8 to the inflammasome to modulate IL-1β production | Q42009946 | ||
| Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1β production in response to β-glucans and the fungal pathogen, Candida albicans | Q42088304 | ||
| Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5 | Q35062839 | ||
| The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease | Q35155012 | ||
| The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes | Q35163583 | ||
| Inflammasome is a central player in the induction of obesity and insulin resistance | Q35216914 | ||
| K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling | Q35328973 | ||
| A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. | Q35350543 | ||
| The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection | Q35528340 | ||
| Critical role for calcium mobilization in activation of the NLRP3 inflammasome | Q36094313 | ||
| Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation | Q36332983 | ||
| Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome | Q36431053 | ||
| Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. | Q36477239 | ||
| High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction | Q36516987 | ||
| NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses | Q36670359 | ||
| Role of caspase-1 in regulation of triglyceride metabolism. | Q36712641 | ||
| Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity | Q36745305 | ||
| The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity | Q36931760 | ||
| Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease | Q37044665 | ||
| AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. | Q37090120 | ||
| Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation | Q37143484 | ||
| Interleukin-18 and IL-18 binding protein | Q37220336 | ||
| Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages | Q37222666 | ||
| Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies | Q37259317 | ||
| Glyburide inhibits the Cryopyrin/Nalp3 inflammasome | Q37387873 | ||
| Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression | Q29615589 | ||
| Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes | Q29615593 | ||
| The NALP3 inflammasome is involved in the innate immune response to amyloid-beta | Q29615595 | ||
| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
| Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling | Q29616024 | ||
| The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance | Q29616026 | ||
| Inflammasomes in health and disease | Q29616356 | ||
| Functional interactions between the gut microbiota and host metabolism | Q29616815 | ||
| Type 2 diabetes as an inflammatory disease | Q29617184 | ||
| Interleukin-1-receptor antagonist in type 2 diabetes mellitus | Q29619001 | ||
| Sterile inflammation: sensing and reacting to damage | Q29620014 | ||
| NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis | Q30519470 | ||
| The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. | Q30582098 | ||
| Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions | Q30865918 | ||
| Malarial hemozoin is a Nalp3 inflammasome activating danger signal | Q33490121 | ||
| Autoimmune T cell responses in the central nervous system | Q33620003 | ||
| Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity | Q33724394 | ||
| Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes | Q33731729 | ||
| Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome | Q33744674 | ||
| Mechanism of NLRP3 inflammasome activation | Q33817836 | ||
| Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes | Q33918445 | ||
| Inflammatory caspases are innate immune receptors for intracellular LPS. | Q34041730 | ||
| The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. | Q34246151 | ||
| Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation | Q34254942 | ||
| An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome | Q34254955 | ||
| IL-1 blockade in autoinflammatory syndromes | Q34262561 | ||
| Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming | Q34343275 | ||
| Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis | Q34401745 | ||
| Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation | Q34410101 | ||
| A critical role for human caspase-4 in endotoxin sensitivity | Q34422142 | ||
| Transcriptome analysis of human adipocytes implicates the NOD-like receptor pathway in obesity-induced adipose inflammation | Q34449332 | ||
| Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies | Q34576478 | ||
| Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity | Q34757980 | ||
| Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets | Q34796756 | ||
| Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation | Q34985696 | ||
| Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome | Q35006409 | ||
| 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome | Q35050189 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammasome complex | Q412405 |
| P304 | page(s) | 677-87 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Inflammasomes: mechanism of action, role in disease, and therapeutics | |
| P478 | volume | 21 |
Search more.